Roth Capital Comments on Aptevo Therapeutics Inc.’s FY2028 Earnings (NASDAQ:APVO)

Aptevo Therapeutics Inc. (NASDAQ:APVO) – Research analysts at Roth Capital issued their FY2028 earnings estimates for Aptevo Therapeutics in a research report issued to clients and investors on Friday, April 19th. Roth Capital analyst J. Aschoff anticipates that the biotechnology company will post earnings per share of $2.76 for the year. The consensus estimate for Aptevo Therapeutics’ current full-year earnings is ($57.83) per share.

Separately, StockNews.com began coverage on shares of Aptevo Therapeutics in a research note on Thursday, April 18th. They set a “sell” rating for the company.

Aptevo Therapeutics Stock Performance

Shares of Aptevo Therapeutics stock opened at $0.71 on Monday. Aptevo Therapeutics has a fifty-two week low of $0.67 and a fifty-two week high of $91.96. The company’s 50 day moving average price is $4.55 and its two-hundred day moving average price is $7.56.

Hedge Funds Weigh In On Aptevo Therapeutics

A hedge fund recently bought a new stake in Aptevo Therapeutics stock. Armistice Capital LLC bought a new position in shares of Aptevo Therapeutics Inc. (NASDAQ:APVO) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 1,235,000 shares of the biotechnology company’s stock, valued at approximately $408,000. Armistice Capital LLC owned about 10.72% of Aptevo Therapeutics as of its most recent SEC filing. 8.06% of the stock is owned by institutional investors.

About Aptevo Therapeutics

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.